Revvity Q3 FY25: where the revenue came from and where it went
The whole income statement of Revvity for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Jun 30 – Sep 28, 2025
- Reported
- Nov 4, 2025
Revenue$0.70B
+2% year over year
Gross profit$0.38B
54% margin
Operating profit$0.08B
12% margin
Net profit$0.05B
7% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 0.70 | 100% | +2% |
| Diagnostics | 0.36 | 51% | +3% |
| Life sciences | 0.34 | 49% | +1% |
| Cost of revenue | −0.32 | 46% | |
| Gross profit | 0.38 | 54% margin | −3pp |
| R&D | −0.05 | 7% | +0pp |
| SG&A | −0.24 | 35% | +0pp |
| Operating profit | 0.08 | 12% margin | −3pp |
| Interest & other costs | −0.03 | ||
| Tax | −0.01 | ||
| Net profit | 0.05 | 7% margin | −7pp |
55 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest